Alpha Teknova (TKNO)
NASDAQ:TKNO
TKNO Stock Chart & Stats
$2.25
-$0.21(-2.33%)
At close: 4:00 PM EST
$2.25
-$0.21(-2.33%)
Day’s Range― - ―
52-Week Range$1.91 - $7.48
Previous CloseN/A
Volume51.57K
Average Volume (3M)318.88K
Market Cap
$151.12M
Enterprise Value$160.35M
Total Cash (Recent Filing)$5.91M
Total Debt (Recent Filing)$15.15M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
May 13, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding53,587,660
10 Day Avg. Volume259,294
30 Day Avg. Volume318,881
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.96
Price to Sales (P/S)5.02
P/FCF Ratio-22.01
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue3.96
Enterprise Value/Gross Profit11.93
Enterprise Value/Ebitda-15.08
Forecast
1Y Price Target
$7.00Price Target Upside211.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$43.01M
Bulls Say, Bears Say
Bulls Say
Commercial ExpansionCompany plans to add field salespeople and increase marketing and tradeshow activity to accelerate commercial expansion and win share in emerging life-science segments.
Product DemandManagement sees rising demand in liquid biopsy diagnostics, next-generation sequencing, and spatial genomics, which could expand product volumes and drive revenue growth.
Profitability ImprovementGrowth in the Clinical Solutions segment alongside cost discipline reduced losses, improved profit margins, and advanced the path toward adjusted EBITDA profitability.
Bears Say
Customer MonetizationAverage revenue per customer has declined as newer customers order less than established accounts, while flat Lab Essentials sales suggest limited revenue expansion from existing customers.
Guidance And Investment NeedsManagement's guidance landed below Street expectations and the company raised the revenue level required to reach adjusted profitability, implying a more cautious near-term outlook and higher planned investments.
Macro And Valuation RiskAnalyst's Neutral rating cites macro headwinds in the life sciences sector and modest growth expectations, leaving the stock vulnerable if sector funding remains constrained.
Alpha Teknova News
TKNO FAQ
What was Alpha Teknova’s price range in the past 12 months?
Alpha Teknova lowest stock price was $1.91 and its highest was $7.48 in the past 12 months.
What is Alpha Teknova’s market cap?
Alpha Teknova’s market cap is $151.12M.
When is Alpha Teknova’s upcoming earnings report date?
Alpha Teknova’s upcoming earnings report date is May 13, 2026 which is in 30 days.
How were Alpha Teknova’s earnings last quarter?
Alpha Teknova released its earnings results on Feb 26, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.093 by $0.003.
Is Alpha Teknova overvalued?
According to Wall Street analysts Alpha Teknova’s price is currently Undervalued.
Does Alpha Teknova pay dividends?
Alpha Teknova does not currently pay dividends.
What is Alpha Teknova’s EPS estimate?
Alpha Teknova’s EPS estimate is -0.09.
How many shares outstanding does Alpha Teknova have?
Alpha Teknova has 53,587,660 shares outstanding.
What happened to Alpha Teknova’s price movement after its last earnings report?
Alpha Teknova reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.093. Following the earnings report the stock price went up 13.158%.
Which hedge fund is a major shareholder of Alpha Teknova?
Currently, no hedge funds are holding shares in TKNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Teknova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (211.11% Upside)
$7.00 (211.11% Upside)
Hedge Fund Trend
Increased
By 244.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $143.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.12%
12-Months-Change
Fundamentals
Return on Equity
-23.32%
Trailing 12-Months
Asset Growth
-5.72%
Trailing 12-Months
Company Description
Alpha Teknova
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
TKNO Company Deck
TKNO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed clear operational and financial progress: revenue growth (6th straight quarter), improved gross margins, narrower net losses and adjusted EBITDA, better free cash flow performance, growing clinical customer count and pipeline progress. Management is beginning to reinvest (~$2M) in commercial capabilities, providing a plausible path to adjusted EBITDA positivity by end of 2027 (targeting $52M–$57M annualized revenue). Key near-term risks include ongoing negative adjusted EBITDA and free cash outflow, lowered average revenue per customer from new/early-stage accounts, revenue lumpiness in Clinical Solutions, and reliance on a sustained biotech funding recovery (with a ~4-quarter lag) to accelerate revenue. Overall, the company is trending in the right direction but still requires execution and favorable market conditions to meet longer-term targets.View all TKNO earnings summariesTKNO Stock 12 Month Forecast
Average Price Target
$7.00
▲(211.11% Upside)
Technical Analysis
Ironwood Pharma
―
Lifecore Biomedical
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―
Ownership Overview
1.31% Insiders
1.98% Mutual Funds
4.12% Other Institutional Investors
90.59% Public Companies and
Individual Investors